Allogene Therapeutics (NASDAQ: ALLO) grants director 95,400 RSUs

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

MESSEMER DEBORAH M. reported acquisition or exercise transactions in this Form 4 filing.

Allogene Therapeutics director Deborah M. Messemer received a grant of 95,400 restricted stock units (RSUs). The award carries no purchase price and gives her the contingent right to receive 95,400 shares of Allogene common stock if the units vest.

According to the terms, the RSUs will vest in two equal semi-annual installments over a one-year period from the grant date, subject to her continued service through each vesting date. Following this grant, she holds 95,400 RSUs directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider MESSEMER DEBORAH M.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Unit	95,400	$0.00	--

Holdings After Transaction: Restricted Stock Unit — 95,400 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

RSUs granted: 95,400 units Underlying common shares: 95,400 shares Vesting schedule: Two equal semi-annual installments over one year

3 metrics

RSUs granted 95,400 units Restricted Stock Unit award to director on 2026-06-18

Underlying common shares 95,400 shares Each RSU equals one share of common stock

Vesting schedule Two equal semi-annual installments over one year Service-based vesting from grant date

Key Terms

Restricted Stock Unit, RSUs, contingent right, semi-annual installments

4 terms

Restricted Stock Unit financial

"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

RSUs financial

"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

contingent right financial

"Each RSU represents a contingent right to receive one share of the Companys Common Stock."

semi-annual installments financial

"The RSUs will vest in two successive equal semi-annual installments over the one-year period"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/23/2026 - 04:34 PM Accepted by SEC EDGAR 06/23/2026 - 04:34 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MESSEMER DEBORAH M.

(Last)

(First)

(Middle)

210 EAST GRAND AVENUE

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Allogene Therapeutics, Inc. [ ALLO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Unit	⁽¹⁾	06/18/2026		A		95,400		⁽¹⁾	⁽¹⁾	Common Stock	95,400	$0	95,400	D

Explanation of Responses:

1. Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date.

Remarks:

	/s/Earl Douglas, Attorney-in-Fact	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Allogene Therapeutics (ALLO) disclose for Deborah M. Messemer?

Allogene disclosed that director Deborah M. Messemer received a grant of 95,400 restricted stock units. These RSUs give her a contingent right to receive the same number of Allogene common shares, subject to vesting conditions linked to continued service.

How many restricted stock units were granted in the latest Allogene (ALLO) Form 4 filing?

The filing shows a grant of 95,400 restricted stock units. Each RSU represents a contingent right to receive one share of Allogene Therapeutics common stock, creating potential equity ownership as the units vest over time.

What is the vesting schedule for Deborah M. Messemer’s Allogene (ALLO) RSU award?

The RSU award will vest in two equal semi-annual installments over one year from the grant date. Vesting is conditional on Deborah M. Messemer’s continued service with Allogene through each scheduled vesting date in that one-year period.

Does the Allogene (ALLO) director pay anything for the 95,400 RSUs granted?

No purchase price is attached to the 95,400 RSUs; the transaction price per unit is reported as 0.0000. The economic value comes from receiving Allogene common shares if the RSUs vest under the stated service-based conditions.

How many Allogene (ALLO) RSUs does Deborah M. Messemer hold after this Form 4 transaction?

After the reported transaction, Deborah M. Messemer holds 95,400 restricted stock units directly. Each RSU is tied to one share of Allogene common stock, providing potential future equity if the units satisfy all vesting requirements.